← Reviews
Jul 10, 2026

Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome

The primary insulin sensitivity endpoint was not met in the full intention-to-treat population; exploratory analyses suggest benefit only in low-baseline Akkermansia subgroups.

Evidence levelBRandomized clinical trial
Study typerct
Sample142
Effect directionNeutral
CertaintyModerate
Clinical applicabilityModerate
Overinterpretation risk1/5 · Low
PICO
Population
Intervention
Comparator
Outcome

What the study showed

Whole-body insulin sensitivity (Matsuda index) did not differ between pasteurized A. muciniphila and placebo after 4 months in the full cohort. Exploratory analyses showed improved hepatic insulin sensitivity and post-OGTT GLP-1 excursion in prediabetic, older (≥63 years), and low-baseline Akkermansia subgroups. Deep metagenomic analysis revealed minor overall microbiota effects of the intervention.

How it was done

Double-blind, placebo-controlled, multicenter RCT (Ireland and Germany) enrolling 142 adults with metabolic syndrome, administered 30 billion cells of pasteurized A. muciniphila MucT daily for 4 months.

Risk of bias

Primary endpoint failure limits the strength of conclusions; positive findings are from post-hoc exploratory analyses subject to multiplicity bias. The sample size may be underpowered for subgroup-level inferences.

Interpretation limit

What this study does NOT prove

This study does not prove that pasteurized A. muciniphila improves insulin sensitivity in the general metabolic syndrome population.

In clinical practice

This trial does not support routine use of pasteurized A. muciniphila for metabolic syndrome. Subgroup findings require prospectively designed confirmatory trials before clinical translation.

Limitations

Primary endpoint failure limits the strength of conclusions; positive findings are from post-hoc exploratory analyses subject to multiplicity bias. The sample size may be underpowered for subgroup-level inferences.

Technical appendix

Version history

  • 1.0 · 2026-07-10 — Auto-generated under Evidence Standard v1.0

Paid access: structured summary from public metadata; consult the original study at the source.

Microbiota Weekly

The week in microbiota evidence, in your language. Structured summaries, traceable to the source.